Ovarian, cervical, and uterine cancer are the most common gynecological malignancies among women worldwide. Cervical cancer is the fourth most frequently occurring cancer in women. It is anticipated that cervical cancer cases will increase from approximately 580,000 in 2018 to 700,000 in 2030, with a rise in the annual number of deaths from 311,000 to 400,000. Gynecological cancers are a result of genomic aberrations controlled by epigenetic factors, acquired and heritable mutations, and transcriptional deviations. A comprehensive understanding of the genomic and molecular framework of gynecologic malignancies is critical in the evolution of potent biomarkers for detection and prevention, molecular profiling, and the development of personalized treatment strategies.
Traditionally, genetic analysis of gynecological malignancies was carried out by analyzing small, single portions of deoxyribonucleic acid (DNA), referred to as Sanger sequencing. Advanced molecular genetic testing, including next-generation sequencing, microarray, polymerase chain reaction, have contributed significantly to deciphering the molecular profile of gynecological cancers in recent years. Advancements in the field of sequencing technologies have supported researchers and clinicians to harness knowledge pertaining to these underlying mutations, which further helped the stakeholders to discover biomarkers for guiding targeted therapeutic decisions.
Next-Generation Gynecological Cancer Diagnostics market to grow at a significant CAGR of 10.07% during 2020-2031. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well. It also aims at answering various aspects of the global next-generation gynecological cancer diagnostics market with the help of the key factors driving the market, restraints, and challenges that can inhibit the overall market growth and the current growth opportunities that are going to shape the future trajectory of the market expansion.
Competitive Landscape
The global next-generation gynecological cancer diagnostics market is currently budding due to the presence of various juggernauts such as Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, Inc., BGI, and PerkinElmer Inc., as well as other medium and small-medium enterprises, that are offering a wide range of next-generation gynecological cancer diagnostics products and services in the market. Several companies are attempting to enter the market and sustain themselves in the competition by adopting different strategies varying from partnerships and collaborations to business expansions and product launches.
Market Growth Drivers
• Subsequent Decline in Next-Generation Sequencing (NGS) Cost
• Increased Recommendations from Government Organizations and Scientific Societies
• Increased Awareness and Shift Toward Personalized Medicine
Market Challenges
• Limited Food and Drug Administration (FDA) Approved Next-Generation Sequencing (NGS) tests
• Complexities Involved with Overall Next-Generation Sequencing (NGS) Process and Result Interpretation
• Reimbursement Challenges Across the Countries
Market Opportunities
• Increased Market Investments and Government Funded Projects
• Next-Generation Sequencing (NGS) Acceptance by Emerging Nations
Key Questions Answered in this Report:
• Which gynecological cancers have been considered in the report?
• What are the key milestones in the development of next-generation gynecological cancer diagnostics?
• What is the scope of next-generation gynecological cancer diagnostics in the future?
• What are the major market drivers, restraints, and opportunities in the global next-generation gynecological cancer diagnostics market?
• What are the key developmental strategies that are being implemented by the key players to sustain this market?
• What is the impact of COVID-19 on the next-generation gynecological cancer diagnostics market?
• What are the guidelines implemented by different government bodies to regulate the approval of next-generation gynecological cancer diagnostics panels and assays?
• How are next-generation gynecological cancer diagnostics being utilized for the development of personalized medicine?
• What is the role of biomarkers in next-generation gynecological cancer diagnostics?
• How will the investments by public and private companies and government organizations affect the global next-generation gynecological cancer diagnostics market?
• What was the market size of the leading segments and sub-segments of the global next-generation gynecological cancer diagnostics market in 2020?
• How will the industry evolve during the forecast period 2021-2031?
• What will be the growth rate of the next-generation gynecological cancer diagnostics market during the forecast period 2021-2031?
• How will each of the segments of the global next-generation gynecological cancer diagnostics market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2031?
• What is the market size of the next-generation gynecological cancer diagnostics market in different countries of the world?
• Which region is expected to contribute to the highest sales of the next-generation gynecological cancer diagnostics market?
• What are the reimbursement scenarios and regulatory structures for the next-generation gynecological cancer diagnostics market in different regions?
• What are the key strategies incorporated by the players of the global next-generation gynecological cancer diagnostics market to sustain the competition and retain their supremacy?
Request Sample- https://bisresearch.com/requestsample?id=1276&type=download
Within the research report, the market has been segmented into ‘product type,’ ‘technology,’ ‘indication,’ ‘end user,’ and ‘regions.’. Each of these segments covers the inclination of the market revenue, underlying patterns, snapshot of the market over the projected years, and trends by using analytics on the primary and secondary data obtained.
BIS Related Studies
Global Rare Disease Diagnostics Market
Global Next-Generation Breast Cancer Diagnostic and Screening Market
U.S. Hematologic Malignancies Testing Market
Global next generation cancer diagnostics market size was worth USD 4,964.05 million in 2016 which is anticipated to grow at a CAGR of more than 9.7% over the forecast period.
The introduction of new products by large bodies, merger, and acquisitions, and joint agreements such as the development of RNA-Seq Kit version by Agilent Technologies Inc. and Agendia Inc. are the factors accountable for the estimated CAGR.An escalation in the development of companion diagnostics in order to deliver advanced and personalized genomic medicine is also responsible for progress in the coming years.Furthermore, the technological advancements driving the innovation in point-of-care testing devices is anticipated to aid in commercialization of advanced products thereby supporting revenue generation.Download Sample Report @ https://www.millioninsights.com/industry-reports/next-generation-cancer-diagnostics-market/request-sampleIncorporation of technological advancements such as melting curve examination for identification of mutations, qPCR tools for profiling of tumor in clinical test centers, and gene deletions are accountable for the largest share apprehended by multiplexing and qPCR segment.With the development of next-generation sequencing technology, the use of traditional methods such as protein and DNA microarrays is expected to decrease through the years.
Other factors such as data interpretation tools, growth of supportive library preparation procedures, and technological advancements are accountable for the lucrative adoption of next generation oncology tests among researchers.Cancer Type InsightsMajor categorization for the types of cancer includes cervical, breast, lung, colorectal, and other tumor forms.
The other types constitute leukemia, prostate, bladder, brain, skin, uterine, esophageal, Non-Hodgkin lymphoma, ovarian, liver, and thyroid.In 2015, as per World Health Organization lung cancer was accountable for approximately 1.7 million deaths.
Moreover, breast cancer incidence is also estimated to grow thereby escalating the demand for screening and diagnostic technologies.Application InsightsGrowth in the number of research schemes to develop novel products and services which enable primary detection of tumor-causing mutations is expected to affect the advancement in genetic analysis over the forecast period.
Biomarker tests offer greater sensitivity in screening and also demonstrate 90% accuracy levels in investigational studies which is attributive to induce progress in the coming years.Function InsightsRisk analysis, prognostic based diagnosis, tumor screening, therapeutic monitoring, & theranostics are the different functions of next generation oncology diagnostic tests.The prognostic diagnostics segment is anticipated to witness the fastest growth in the coming years as a consequence of higher adoption of prognosis which plays important role in designing oncology therapies and protocols for chemotherapy, radiation-based treatment, and gene therapy.Regional InsightsThe next generation cancer diagnostics market is dominated by North America with approximately 40% market share.
Next Generation Cancer Diagnostics Industry research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period.Get FREE Sample Report Before Buying @ https://www.upmarketresearch.com/home/requested_sample/8213UpMarketResearch offers a latest published report on “Global Next Generation Cancer Diagnostics Market Analysis and Forecast 2018-2023” delivering key insights and providing a competitive advantage to clients through a detailed report.
The report contains 109 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.Next Generation Cancer Diagnostics Industry research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period.
Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
The numerical data is backed up by statistical tools such as SWOT analysis, BCG matrix, SCOT analysis, PESTLE analysis and so on.
The statistics are represented in graphical format for a clear understanding on facts and figures.The generated report is firmly based on primary research, interviews with top executives, news sources and information insiders.
Secondary research techniques are implemented for better understanding and clarity for data analysis.The report for Next Generation Cancer Diagnostics market analysis & forecast 2018-2023 is segmented into Product Segment, Application Segment & Major players.Region-wise Analysis Global Next Generation Cancer Diagnostics Market covers:North AmericaEuropeChinaJapanIndiaSoutheast AsiaOther regions (Central & South America, Middle East & Africa)The Major players reported in the market include:CepheidKoninklijke Philips N.VHoffmann-La Roche LtdQiagenNovartis AGAbbottThermo Fisher ScientificOpko HealthMyriad GeneticsAgilent TechnologiesGE HealthcarePerkinElmerGenomic HealthIlluminaHologicAlmac GroupJanssen Global ServicesSysmex CorporationFor More Information, Please Visit https://www.upmarketresearch.com/home/enquiry_before_buying/8213Global Next Generation Cancer Diagnostics Market: Product Segment Analysis:Next Generation SequencingqPCR & MultiplexingDNA MicroarraysOtherGlobal Next Generation Cancer Diagnostics Market: Application Segment Analysis:HospitalsClinicsOtherThe Report covers in-depth analysis as follows:Chapter 1 Report OverviewChapter 2 Global Growth TrendsChapter 3 Market Share by Key PlayersChapter 4 Breakdown Data by Type and ApplicationChapter 5 United StatesChapter 6 EuropeChapter 7 ChinaChapter 8 JapanChapter 9 Southeast AsiaChapter 10 IndiaChapter 11 Central & South AmericaChapter 12 International Players ProfilesChapter 13 Market Forecast 2018-2025Chapter 14 Analyst's Viewpoints/ConclusionsChapter 15 AppendixBuy Next Generation Cancer Diagnostics Market analysis & forecast 2018-2023 Report along with complete TOC @ https://www.upmarketresearch.com/buy/next-generation-cancer-diagnostics-market“Next Generation Cancer Diagnostics Market Analysis and Forecast 2018-2023” report helps the clients to take business decisions and to understand strategies of major players in the industry.
